Increased Rate of Anemia and Discontinuation in Older Patients with Myelofibrosis Treated with Ruxolitinib.

ABSTRACT: Background/Objectives: Myelofibrosis (MF) predominantly affects older individuals, and its incidence increases with age. Ruxolitinib (RUX), a JAK1/2 inhibitor, effectively reduces spleen volume and relieves disease-related symptoms in MF patients and can be prescribed regardless of age. Although advanced age is associated with poorer MF prognosis, the influence of patient age on RUX treatment efficacy and safety has not been fully elucidated. Methods: In this single-center, retrospective study, we included 216 adult MF patients who initiated RUX therapy between 2012 and 2024. Patients were stratified by age at the start of RUX as follows: <65 (n = 105), 65-74 (n = 64), and ≥75 years (n = 47). Clinical data were analyzed in order to assess the impact of ag

SUBMITTER: Lagana A 

PROVIDER: S-EPMC12524875 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature